Comparison of the hepatic metabolism of triazolam in wild-type andCyp3a-knockout mice for understanding CYP3A-mediated metabolism inCYP3A-humanised mice in vivo

References

• Abe S, Kobayashi K, Oji A, et al. (2017). Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology. Sci Rep 7:15189.
   PubMed Web of Science ®Google Scholar
• Aueviriyavit S, Kobayashi K, Chiba K. (2010). Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. Drug Metab Pharmacokinet 25:93–100.
   PubMed Web of Science ®Google Scholar
• Burkina V, Rasmussen MK, Pilipenko N, et al. (2017). Comparison of xenobiotic-metabolising human, porcine, rodent, and piscine cytochrome P450. Toxicology 375:10–27.
   PubMed Web of Science ®Google Scholar
• Cui JY, Klaassen CD. (2016). RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. Biochim Biophys Acta 1859:1198–217.
   PubMed Web of Science ®Google Scholar
• Dufek MB, Knight BM, Bridges AS, et al. (2013). P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism. Drug Metab Dispos 41:642–50.
   PubMed Web of Science ®Google Scholar
• Eberts FS, Jr, Philopoulos Y, Reineke LM, et al. (1981). Triazolam disposition. Clin Pharmacol Ther 29:81–93.
   PubMed Web of Science ®Google Scholar
• Granvil CP, Yu AM, Elizondo G, et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548–58.
   PubMed Web of Science ®Google Scholar
• Graves JP, Gruzdev A, Bradbury JA, et al. (2017). Characterization of the tissue distribution of the mouse Cyp2c subfamily by quantitative PCR analysis. Drug Metab Dispos 45:807–16.
   PubMed Web of Science ®Google Scholar
• Grimsley A, Gallagher R, Hutchison M, et al. (2013). Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam. Biochem Pharmacol 86:529–38.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kapelyukh Y, Tahara H, et al. (2011). Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518–28.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kobayashi K, Watanabe M, et al. (2013). Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver. J Lipid Res 54:2060–8.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kobayashi K, Yamazaki M, et al. (2016). Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. J Steroid Biochem Mol Biol 163:121–8.
   PubMed Web of Science ®Google Scholar
• Henderson CJ, McLaughlin LA, Scheer N, et al. (2015). Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol 87:733–9.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Sharma A, Shukla M, et al. (2014). Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models. Drug Metab Rev 46:475–93.
   PubMed Web of Science ®Google Scholar
• Johnson CH, Bonzo JA, Cheng J, et al. (2013). Cytochrome P450 regulation by α-tocopherol in Pxr-null and PXR-humanized mice. Drug Metab Dispos 41:406–13.
   PubMed Web of Science ®Google Scholar
• Kazuki Y, Kobayashi K, Aueviriyavit S, et al. (2013). Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum Mol Genet 22:578–92.
   PubMed Web of Science ®Google Scholar
• Kim RB, Wandel C, Leake B, et al. (1999). Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408–14.
   PubMed Web of Science ®Google Scholar
• Konno Y, Kamino H, Moore R, et al. (2010). The nuclear receptors constitutive active/androstane receptor and pregnane x receptor activate the Cyp2c55 gene in mouse liver. Drug Metab Dispos 38:1177–82.
   PubMed Web of Science ®Google Scholar
• Ly JQ, Messick K, Qin A, et al. (2017). Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug-drug interactions. Mol Pharm 14:1754–9.
   PubMedGoogle Scholar
• Matheny CJ, Ali RY, Yang X, et al. (2004). Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 32:1008–14.
   PubMed Web of Science ®Google Scholar
• Moore LB, Parks DJ, Jones SA, et al. (2000). Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–7.
   PubMed Web of Science ®Google Scholar
• Patki KC, von Moltke LL, Harmatz JS, et al. (2004). Effect of age on in vitro triazolam biotransformation in male human liver microsomes. J Pharmacol Exp Ther 308:874–9.
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, et al. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618–28.
   PubMed Web of Science ®Google Scholar
• Staudinger J, Liu Y, Madan A, et al. (2001a). Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29:1467–72.
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, et al. (2001b). The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369–74.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Fukami T, Masuo Y, et al. (2016). Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J Lipid Res 57:2130–7.
   PubMed Web of Science ®Google Scholar
• ter Heine R, Van Waterschoot RA, Keizer RJ, et al. (2011). An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. J Pharm Sci 100:2508–15.
   PubMed Web of Science ®Google Scholar
• Tian D, Hu Z. (2014). CYP3A4-mediated pharmacokinetic interactions in cancer therapy. Curr Drug Metab 15:808–17.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (U.S. FDA) (2017). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. [Accessed 31 Aug 2018].
   Google Scholar
• van Herwaarden AE, Smit JW, Sparidans RW, et al. (2005). Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 33:892–5.
   PubMed Web of Science ®Google Scholar
• van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583–92.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, van Herwaarden AE, Lagas JS, et al. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029–36.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Lagas JS, Wagenaar E, et al. (2009a). Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996–9002.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Rooswinkel RW, Sparidans RW, et al. (2009b). Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305–13.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Rooswinkel RW, Wagenaar E, et al. (2009c). Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. Faseb J 23:224–31.
   PubMed Web of Science ®Google Scholar
• Varhe A, Olkkola KT, Neuvonen PJ. (1994). Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601–7.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, et al. (1996). Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370–9.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Granda BW, Grassi JM, et al. (2004). Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab Dispos 32:800–4.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Kobayashi K, Okuya F, et al. (2018). Characterization of P-glycoprotein humanized mice generated by chromosome engineering technology: its utility for prediction of drug distribution to the brain in humans. Drug Metab Dispos 46:1756–66.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou Z, Tay-Sontheimer J, et al. (2018). Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016. Drug Metab Dispos 46:835–45.
   PubMed Web of Science ®Google Scholar